Alnylam Pharmaceuticals (ALNY): $0.13 million was the positive money flow into the stock on Thursday and the up/down ratio of ticks was also in favor of the bulls at 1.6. The value of trades done on upticks was $0.35 million, whereas, trades done on downticks were valued at $0.22 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $0.1 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $0.1 million. Alnylam Pharmaceuticals (ALNY) fell $0.72 traded at $62.1, a change of -1.15% over the previous day. The stock is -0.13% for the week.
The stock has recorded a 20-day Moving Average of 7.94% and the 50-Day Moving Average is 4.62%. Shares have dropped -50.78% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $137.89 and the one year low was seen on May 12, 2016. The 50-Day Moving Average price is $61.95 and the 200 Day Moving Average price is recorded at $65.41.
Alnylam Pharmaceuticals (NASDAQ:ALNY): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $63.43 and $61.57 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $63.43. The buying momentum continued till the end and the stock did not give up its gains. It closed at $63.01, notching a gain of 0.30% for the day. The total traded volume was 562,543 . The stock had closed at $62.82 on the previous day.
In an insider trading activity, Maraganore John, director officer (Chief Executive Officer) of Alnylam Pharmaceuticals, Inc., unloaded 30,151 shares at an average price of $67.87 on April 19, 2016. The total amount of the transaction was worth $2,046,348, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.